Pharmacokinetics and pharmacodynamics of posaconazole for invasive pulmonary aspergillosis: clinical implications for antifungal therapy - Wikidata - awgldk - TriplyDB

Pharmacokinetics and pharmacodynamics of posaconazole for invasive pulmonary aspergillosis: clinical implications for antifungal therapy

Pharmacokinetics and pharmacodynamics of posaconazole for invasive pulmonary aspergillosis: clinical implications for antifungal therapy

http://www.wikidata.org/entity/Q34754956

about

Combination of voriconazole and anidulafungin for treatment of triazole-resistant aspergillus fumigatus in an in vitro model of invasive pulmonary aspergillosis Comparative pharmacodynamics of posaconazole in neutropenic murine models of invasive pulmonary aspergillosis and mucormycosis.A novel fungus concentration-dependent rat model for acute invasive fungal rhinosinusitis: an experimental study.Posaconazole prophylaxis in experimental azole-resistant invasive pulmonary aspergillosis.The strength of synergistic interaction between posaconazole and caspofungin depends on the underlying azole resistance mechanism of Aspergillus fumigatus.Pharmacodynamics of echinocandins against Candida glabrata: requirement for dosage escalation to achieve maximal antifungal activity in neutropenic hosts Pharmacodynamics of isavuconazole in an Aspergillus fumigatus mouse infection model Antifungal pharmacokinetics and pharmacodynamics Posaconazole exposure-response relationship: evaluating the utility of therapeutic drug monitoring.Pharmacodynamics of itraconazole against Aspergillus fumigatus in an in vitro model of the human alveolus: perspectives on the treatment of triazole-resistant infection and utility of airway administration.Echinocandin Resistance in Candida.Pharmacodynamics of anidulafungin against clinical Aspergillus fumigatus isolates in a nonneutropenic murine model of disseminated aspergillosis.Posaconazole pharmacodynamic target determination against wild-type and Cyp51 mutant isolates of Aspergillus fumigatus in an in vivo model of invasive pulmonary aspergillosis In vitro interaction of voriconazole and anidulafungin against triazole-resistant Aspergillus fumigatus.Tacrolimus enhances the potency of posaconazole against Rhizopus oryzae in vitro and in an experimental model of mucormycosis Pharmacodynamics and dose-response relationships of liposomal amphotericin B against different azole-resistant Aspergillus fumigatus isolates in a murine model of disseminated aspergillosis Impact of in vivo triazole and echinocandin combination therapy for invasive pulmonary aspergillosis: enhanced efficacy against Cyp51 mutant isolates Isavuconazole (BAL4815) pharmacodynamic target determination in an in vivo murine model of invasive pulmonary aspergillosis against wild-type and cyp51 mutant isolates of Aspergillus fumigatus.Intrapulmonary posaconazole penetration at the infection site in an immunosuppressed murine model of invasive pulmonary aspergillosis receiving oral prophylactic regimens.Current concepts in antifungal pharmacology.Echinocandin resistance, susceptibility testing and prophylaxis: implications for patient management.Mechanisms of Antifungal Drug Resistance.Mechanisms of echinocandin antifungal drug resistance.Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.Posaconazole-Loaded Leukocytes as a Novel Treatment Strategy Targeting Invasive Pulmonary Aspergillosis.Pharmacodynamics for antifungal drug development: an approach for acceleration, risk minimization and demonstration of causality.Prognostic value of galactomannan: current evidence for monitoring response to antifungal therapy in patients with invasive aspergillosis.Concentration of antifungal agents within host cell membranes: a new paradigm governing the efficacy of prophylaxis Animal Models for Studying Triazole Resistance in Aspergillus fumigatus.Pharmacodynamics of the Orotomides against Aspergillus fumigatus: New Opportunities for Treatment of Multidrug-Resistant Fungal Disease.In Vivo Efficacy of Liposomal Amphotericin B against Wild-Type and Azole-Resistant Aspergillus fumigatus Isolates in Two Different Immunosuppression Models of Invasive Aspergillosis.In Vivo Synergy of Amphotericin B plus Posaconazole in Murine Aspergillosis.A reference laboratory experience of clinically achievable voriconazole, posaconazole, and itraconazole concentrations within the bloodstream and cerebral spinal fluid Pharmacodynamics of the Novel Antifungal Agent F901318 for Acute Sinopulmonary Aspergillosis Caused by Aspergillus flavus.Pharmacodynamics of voriconazole in a dynamic in vitro model of invasive pulmonary aspergillosis: implications for in vitro susceptibility breakpoints.Pharmacokinetics of Intravenous Posaconazole in Critically Ill Patients.A strategy for designing voriconazole dosage regimens to prevent invasive pulmonary aspergillosis based on a cellular pharmacokinetics/pharmacodynamics model.Azole Resistance in Aspergillus fumigatus: Mechanisms, Route of Resistance Selection, and Clinical Implications Can We Achieve Clinical Breakpoints for the Triazoles in Aspergillosis?A Disposable Carbon Nanotubes-screen Printed Electrode (CNTs-SPE) for Determination of the Antifungal Agent Posaconazole in Biological Samples

P2860

Q28727508-A62BCA2C-E6EF-4853-928A-05238B4FFAC0 Q34596761-1E3B8606-5BB1-40CC-BE48-C3EBDEFE3DD7 Q34978951-E569D0F6-C791-4E82-B2FA-EBB57D36E676 Q35076830-BA155BE7-F6F6-43F9-BA2A-5CDF42ECDAAB Q35076940-F3A5608C-1B24-4A9D-B3ED-76C9940D390C Q35270758-5B5A3EC7-3B30-4E17-B036-261B545B1D19 Q35385554-87B78BFC-2AE2-426E-8115-648C9A1A5204 Q35663841-11BDF06B-1A0A-4730-8945-5E8DF4291A1F Q36018743-F0BAE570-B37D-4E78-B3A8-F6B1B856562E Q36171643-82634B34-5B08-4FA6-A6EF-F70227898F74 Q36276186-3795AC7B-3CD0-48C7-889A-95281635A878 Q36505281-FEC21A83-3A5C-402B-9A7F-21E463B9F860 Q36505539-0E2C9880-D71C-48B8-9AF1-B1628685FCA5 Q36558484-F94DC98C-83D3-421B-BF43-9E7A2D343E4B Q36584655-CA7F5050-7184-42FA-A6ED-4960F6F8543B Q36757621-FB4E51A9-AA41-4014-B5A5-0EB7DB2AD0D0 Q37263430-3348D64A-821F-45CD-934F-AA3F78ED0BD7 Q37335649-506FAF5C-EFD0-46DE-90BF-D2630A001653 Q37713035-18372AE5-E47C-4CED-9736-D9AD1E3F8063 Q37908856-7691784C-605A-45AD-96DA-D8D723E46CB9 Q38254290-C3042AC8-7E22-438A-B16F-28A21DB1E86C Q38266675-E11F4CBD-1455-4700-B6F4-7350F9F70209 Q38550402-FC67A903-F42D-4A81-80DB-94A9B7376E6E Q38681635-B7D91CC0-0D1C-41CC-A103-1D326381B836 Q38734661-8773AD75-14B4-4616-8219-16C885A75B74 Q38919690-004285F7-3C1D-4066-89E8-AE476D3B6C3B Q39127825-01BEE552-9291-42E0-9513-94DBE478C52F Q39471624-A87DA59D-C1DE-4130-A1E2-188B0599A2B4 Q40045642-BEC94EA1-D2A4-41FB-BC1E-AD204CFCFD77 Q40083822-83C8816F-784A-4D5B-87F9-51E78C128127 Q40248126-C8177F91-D45A-47E5-A3B8-D7A009B1EDE4 Q40936437-9779B1CA-059F-4E9D-B34B-ED94AADD479E Q41907424-7FDEA5AD-4095-4EE5-9D5A-25895FA8FC02 Q46583730-CF1B7C60-CC1A-4B2B-999B-35E972C54C94 Q47568169-82470298-1A07-4E09-A193-9E843B667E18 Q55236793-E2E064A3-C58C-4044-B87B-2A8B2DD1EE2C Q55479804-6ABA3402-B604-418E-A31A-DCF771E98581 Q56993256-B12CADA3-2C0B-46E1-8632-E0C7A8936624 Q57518528-BD49A125-79AF-4AD9-8249-9A2B5AA394DF Q57688503-0B9BA110-ED69-4D4D-8575-6112999296FC

P2860

Pharmacokinetics and pharmacodynamics of posaconazole for invasive pulmonary aspergillosis: clinical implications for antifungal therapy

http://www.wikidata.org/entity/Q34754956

description

2011 nî lūn-bûn

@nan

2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Pharmacokinetics and pharmacod ...... cations for antifungal therapy

@ast

Pharmacokinetics and pharmacod ...... cations for antifungal therapy

@en

Pharmacokinetics and pharmacod ...... cations for antifungal therapy

@nl

type

label

Pharmacokinetics and pharmacod ...... cations for antifungal therapy

@ast

Pharmacokinetics and pharmacod ...... cations for antifungal therapy

@en

Pharmacokinetics and pharmacod ...... cations for antifungal therapy

@nl

prefLabel

Pharmacokinetics and pharmacod ...... cations for antifungal therapy

@ast

Pharmacokinetics and pharmacod ...... cations for antifungal therapy

@en

Pharmacokinetics and pharmacod ...... cations for antifungal therapy

@nl

P1433

Q34754956-53A48270-DE21-4B47-8554-98F0CD3CEEBA

P1476

Q34754956-18E63F59-19E6-47B7-8C8C-CCEF69A0DF96

P2093

Q34754956-1DEE8C36-29BC-494A-B8A7-136F4ED477F8

Q34754956-5C5A5589-5B9F-4B3D-AB63-7C4B39713862

Q34754956-64A61C30-14C5-4E46-BAC7-A9B7E99D7B69

Q34754956-B7BEC092-E510-4038-B1F7-57F71014A65B

Q34754956-C70A0DD8-7FBC-482E-8C8F-54C185C85670

Q34754956-D25EF36F-B813-43DA-9175-9450E9040729

Q34754956-EF450CFD-7D8A-46FF-B3A1-23A076CAECFA

P2860

Q34754956-036725D0-E1EB-46D0-B8DE-1B85DF068F36

Q34754956-4449F677-4223-4C3C-B825-685B1484A229

Q34754956-462809DB-011B-4B74-A9D6-25E19B1D0052

Q34754956-48B34384-A9B8-4FBC-B1EC-FD924EE32793

Q34754956-7D3A3C9D-F1B7-49DC-917E-EB68305B419D

Q34754956-81946B98-1457-4BCD-BAEC-24F45EC86427

Q34754956-91C10E77-785E-4F66-A6BE-7A36D10484C5

Q34754956-95AE4922-8ADD-4CAD-B942-FDF0042D9BE3

Q34754956-9F296AD2-BE8A-4538-B5EC-750712D9E491

Q34754956-A5F1682B-9041-449B-933B-10DA1752C161

P304

Q34754956-7ABADF8C-0A84-4782-BA65-79256B6E3A20

P31

Q34754956-EF77E287-3BEB-4AC0-95E2-2FB1700B6C1E

P356

Q34754956-A2B5B853-7657-46DC-B894-68180F40CDDD

P407

Q34754956-2696F68E-B8EE-43A4-9612-F20E00BBF15B

P433

Q34754956-7686E218-8FF7-4E94-AA83-617F751DC5FA

P478

Q34754956-1FE357DC-605A-47D0-907D-41D75F3C65E7

P50

Q34754956-9E90CB52-8CBB-4B58-B20E-C85CF29A58DA

Q34754956-BCFB6BDB-F682-481C-B2A0-0568BF31A438

P577

Q34754956-2AF8ED84-1115-4EC1-A403-51209F41A81D

P5875

Q34754956-5F4929CE-E7F4-416E-9300-6AC3C563D7C7

P698

Q34754956-0EA98F66-B5EA-4559-8E78-42AD47364C0D

P921

Q34754956-207467F9-4264-470D-997F-E61B3A1296B8

P932

Q34754956-0F3EBEE4-BBD9-4397-9D11-523F663121CF

P356

P1433

The Journal of Infectious Diseases

P1476

Pharmacokinetics and pharmacod ...... cations for antifungal therapy

@en

P2093

Andrew Sharp

http://www.w3.org/2001/XMLSchema#string

Jayesh B Majithiya

http://www.w3.org/2001/XMLSchema#string

Joanne Goodwin

http://www.w3.org/2001/XMLSchema#string

Joanne Slater

http://www.w3.org/2001/XMLSchema#string

Lea Gregson

http://www.w3.org/2001/XMLSchema#string

Peter A Warn

http://www.w3.org/2001/XMLSchema#string

Susan J Howard

http://www.w3.org/2001/XMLSchema#string

P2860

Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial

Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia

Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia

Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene.

Prognostic features of galactomannan antigenemia in galactomannan-positive invasive aspergillosis

Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection

Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease.

Posaconazole: a broad-spectrum triazole antifungal.

Antifungal pharmacokinetics and pharmacodynamics: bridging from the bench to bedside.

Therapy for fungal diseases: opportunities and priorities.

P304

1324-1332

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/INFDIS/JIR023

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

203

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-02-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

50227038

http://www.w3.org/2001/XMLSchema#string

P698

21357943

http://www.w3.org/2001/XMLSchema#string

P921

P932

3069735

http://www.w3.org/2001/XMLSchema#string